Zydus Lifesciences rises on getting USFDA’s tentative nod for Empagliflozin and Linagliptin Tablets

28 Nov 2025 Evaluate

Zydus Lifesciences is currently trading at Rs. 941.00, up by 3.75 points or 0.40% from its previous closing of Rs. 937.25 on the BSE.

The scrip opened at Rs. 945.10 and has touched a high and low of Rs. 947.15 and Rs. 936.50 respectively. So far 27925 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 797.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 949.25 and Rs. 921.05 respectively. The current market cap of the company is Rs. 94284.12 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.20% and 6.80% respectively.

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg (USRLD: Glyxambi Tablets, 10mg/5 mg and 25 mg/5 mg).

Empagliflozin and Linagliptin Tablets (10 mg/5 mg and 25 mg/5 mg) in a combination are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. Empagliflozin and Linagliptin Tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad. Empagliflozin and Linagliptin Tablets had annual sales of $215.8 million in the United States (IQVIA MAT Sept-2025). The group now has 428 approvals and has so far filed 487 ANDAs since the commencement of the filing process in FY 2003-04. 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. 

Zydus Lifesciences Share Price

934.25 -0.95 (-0.10%)
05-Dec-2025 13:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.65
Dr. Reddys Lab 1278.00
Cipla 1524.55
Zydus Lifesciences 934.25
Lupin 2102.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×